Alzheimer Disease Biomarkers and Assisted Dying

The article discusses the expansion of blood-based biomarker testing for Alzheimer disease diagnosis. It outlines communication strategies between patients and physicians regarding end-of-life questions and physician-assisted death options. Blood-based biomarkers represent a new opportunity for early detection of Alzheimer disease. The article emphasizes the importance of effective communication between healthcare professionals and patients when addressing sensitive topics related to end-of-life care. The goal is to provide patients and their families with information necessary to make informed decisions about their care.